Swiss Electrical Stock News

Roche Holding stock has delivered a 60.7% return over the past three years, and the recent run raises the question of whether the current price still lines up with what the valuation checks suggest. Over the past 3 years, Roche Holding has returned 60.7%, which puts recent gains front and centre in any assessment of what investors are now paying for the stock. Large ongoing investments in U.S. manufacturing capacity and diagnostics partnerships can support future cash generation. However,...

SIG Group AG recently appointed Ann-Kristin Erkens as CEO, replacing Mikko Keto, as its transformation programme delivered higher adjusted EBIT margins and stronger free cash flow, while the company reiterated its 2026 outlook and focus on aseptic system solutions. The planned Capital Markets Day in October, where SIG will outline its updated strategy and mid-term targets, gives investors a clearer lens on how the transformation programme could influence future business priorities and...

DKSH Holding (SWX:DKSH) is back in focus after its Malaysian unit reported a 34.8% year-on-year jump in second quarter net profit, supported by higher revenue and unrealised foreign exchange gains. See our latest analysis for DKSH Holding. At a share price of CHF66.40, DKSH Holding has seen its 30 day share price return of 3.75% and year to date share price return of 13.31%. The 1 year total shareholder return is 19.71%, which suggests momentum has been building rather than fading...

Sika (SWX:SIKA) has drawn fresh investor attention after issuing €1b in hybrid capital bonds split into two callable, subordinated tranches, while S&P shifted its issuer rating outlook on the company from Negative to Stable. See our latest analysis for Sika. For investors, the hybrid bond issuance and S&P outlook revision arrive as Sika’s share price shows renewed momentum, with a 30-day share price return of 17.92% and a 90-day gain of 25.14%, even though the 5-year total shareholder return...

Barclays is once again reshaping its investment bank, cutting leadership, tightening capital and leaning harder on its markets division. That shift could leave more room for UK and European retail and wealth focused banks that rely on simpler deposit and lending models rather than capital intensive trading and dealmaking. This article walks through three stocks exposed to that story and explains how the recent shake up might matter for your portfolio decisions. The three stocks covered below...

Schindler Holding wins high profile New York modernization contract Schindler Holding (SWX:SCHN) has secured the modernization of 31 elevators at the General Motors Building in Midtown Manhattan, a high profile project that features its PORT destination system in a heavily trafficked office tower. See our latest analysis for Schindler Holding. The GM Building contract comes at a time when Schindler Holding’s share price has shown a 3.69% gain over the past month, while its year-to-date share...

Galenica AG recently reported past half-year 2026 results, with sales rising to CHF 2,136.45 million and revenue to CHF 2,143.28 million, while net income decreased to CHF 66.35 million and earnings per share eased compared with the prior year period. Despite the softer profitability, management confirmed its 2026 outlook for consolidated net sales growth of 5.7% and EBIT growth between 6% and 8%, underscoring confidence in the business trajectory. With Galenica confirming its 2026 earnings...

Sunrise Communications stock came into today looking bruised, with the share price drifting down roughly 3% over the past month and about 3% over the last quarter. The long term pitch around a cheap telecom with a turnaround story met some hard numbers in the latest release. Revenue for the last twelve months sat at CHF 2.98b while the company still reported a loss from continuing operations and negative earnings per share. The real headline is not growth but pressure. Profitability remains...

DocMorris stock closed at CHF10.00 on the day of its latest earnings, capping a volatile few months that included a sharp rebound over the past quarter. The market has been treating DocMorris as a high growth, online pharmacy bet. The headline from the latest numbers is more sobering. Revenue over the last twelve months reached about CHF1.1b, yet the company still reported a sizeable loss from continuing operations and a loss per share in the mid single digit CHF range. The expectation gap is...

Straumann Holding stock closed at CHF97.22 on the day its latest figures landed, well below an internal discounted cash flow estimate of CHF160.06. The market has been trimming exposure in recent weeks; yet the fresh numbers highlight a different story. Earnings sit on a compressed 13.7% net profit margin after a CHF136.0m one off loss in the last twelve months, while the P/E of 43.5x prices Straumann as a premium dental equipment play. The key question for you is whether that margin squeeze...

SIG Group (SWX:SIGN) abruptly replaced CEO Mikko Keto with former CFO Ann-Kristin Erkens less than six months into Keto’s tenure, raising questions about leadership stability despite reaffirmed guidance and an upcoming Capital Markets Day. See our latest analysis for SIG Group. For context, SIG Group’s 1 day share price return of 1.31% comes after a sharp 7 day share price decline of 14.20%. The 90 day share price return of 11.99% and year to date share price return of 14.92% contrast with a...

Phoenix Mecano stock closed at CHF443 today, only slightly above where it was trading a month ago, even after investors digested fresh half year numbers. The headline from these results is not the modest revenue move. It is the sharp jump in operating profitability, with earnings before interest and tax up 23.5% on the back of stronger margins in the industrial units. Over a longer horizon the story shifts to valuation. The stock trades on a trailing P/E of 14x, while peers sit much higher...

SKAN Group stock has been on a tear into this earnings print, closing at CHF62.70 and logging a roughly 32% gain over the past three months. That kind of run sets a high bar for a specialised pharma equipment supplier. The headline from H1 is clear. SKAN Group delivered a sharp reset in profitability with net profit of CHF5.4m and an EBITDA margin of 9.3% on CHF164.5m of net sales. Order intake of CHF247.6m and a CHF442m backlog reflect why the growth story still commands a premium P/E...

Novartis stock has delivered a strong 88.5% return over the past five years, and the valuation checks now point to a company that looks undervalued on market multiples but not as a straightforward bargain across every metric. Over the past 5 years, Novartis has returned 88.5%, which puts recent short term ups and downs into the context of a solid multi year share price performance. Protecting cash flows from key products such as Entresto, supported by the recent UK court win on its patent,...

Sandoz Group AG recently announced a collaboration agreement with Shanghai Henlius Biotech, Inc. to develop, manufacture and commercialise up to 10 biosimilars, including proposed versions of cetuximab, evolocumab and belimumab, with Henlius handling development and manufacturing and Sandoz holding commercial rights outside China under a milestones-based deal of up to US$322 million. This partnership lifts Sandoz’s biosimilar pipeline from 39 assets with potential to reach up to 46,...

Why ABB stock is drawing fresh attention after the LevelTen Energy deal ABB (SWX:ABBN) is back in focus after announcing a partnership and minority investment in LevelTen Energy, tying its electrification and energy management tools more tightly to global clean energy procurement. See our latest analysis for ABB. The LevelTen Energy announcement lands at a time when ABB's share price has gained clear momentum, with a 30 day share price return of 4.8% and a year to date share price return of...

With Michael Burry comparing the AI-fuelled rally to past bubbles and the CAPE ratio sitting close to its late 1999 peak, investors are watching a market where optimism and risk sit side by side. Trading venues and options infrastructure stocks can sit right in the slipstream of that activity. This article looks at three stocks exposed to the current news narrative and explains why their stories might deserve a place on your watchlist. The three stocks below are only a starting sample, and...

In the second quarter and first half of 2026, Alcon Inc. reported higher sales and revenue year on year, but net income for the six-month period fell to US$189 million from US$526 million, with basic and diluted earnings per share from continuing operations both dropping to US$0.39 from US$1.06. Even as Alcon maintained its full-year 2026 net sales growth guidance of 5% to 7%, the combination of rising revenue, lower profitability, and mixed valuation signals has sharpened investor focus on...

Rising reports of violent homejackings around Lake Geneva are testing Switzerland’s image as a safe harbour for wealth, and that shift is drawing fresh attention to security and surveillance technology providers. When reputations and high end assets feel exposed, demand for better protection often moves quickly. This article walks through three stocks tied to these security themes and explains how the recent news could matter for their long term story. The stocks covered below are just a...

How Swisscom’s latest earnings update is shaping investor focus Swisscom (SWX:SCMN) drew fresh attention on 6 August 2026 after reporting half year results that combined lower sales of CHF 7,221 million with higher net income of CHF 669 million and basic EPS of CHF 12.92. See our latest analysis for Swisscom. Since the start of the year Swisscom’s share price has gained 10.36%, while the stock is down 5.47% over the past 90 days, and the 1 year total shareholder return of 14.85% points to...

Restylane Shaype launch puts Galderma Group in focus Galderma Group (SWX:GALD) has drawn fresh investor attention after securing European Union approval for Restylane Shaype, a hyaluronic acid gel designed specifically for minimally invasive chin shaping and augmentation. See our latest analysis for Galderma Group. The Restylane Shaype approval lands at a time when Galderma Group’s share price has eased in the very short term, with the 1 day and 7 day share price returns declining 3.11% and...

Swiss Re (SWX:SREN) is drawing fresh attention after its H1 2026 results, with net income of US$2.831b and basic earnings per share of US$9.57 for the six months to June 30. See our latest analysis for Swiss Re. Swiss Re's share price has climbed over the past quarter, with a 90 day share price return of 14.82% and a year to date share price return of 7.15%. The 3 year total shareholder return of 93.41% highlights how long term holders have been rewarded, as recent earnings keep interest in...

Komax Holding shares closed at CHF78.70 on Friday, only modestly higher over the past week and month, which suggests investors came into these results cautiously optimistic but not euphoric. The earnings headline is simple and uncomfortable. The wiring automation specialist is still loss making, with a basic earnings per share loss of CHF0.96 in the first half and trailing twelve month losses that remain in the mid single digit millions of francs. The key issue now is valuation. The stock...

Alcon (SWX:ALC) is back in focus after its second quarter 2026 earnings report. The results showed higher sales and revenue but a much lower net income figure, giving investors mixed signals to digest. See our latest analysis for Alcon. The recent earnings announcement, maintained 2026 net sales growth guidance, and the RxSight collaboration have come alongside a 90 day share price return of 17.97%, although the 1 year total shareholder return is down 13.93%. If this mix of earnings and...